Navigation Links
Vaccine Shields Monkeys From Simian Form of HIV
Date:5/17/2009

Scientists inject antibody-coding genes directly into muscles

SUNDAY, May 17 -- Raising hopes for the development of an AIDS vaccine that might actually work, researchers report they were able to protect monkeys against infection with simian immunodeficiency virus (SIV), the primate version of HIV.

They did so by using a novel approach that delivered antibody-producing genes directly to the animals' muscles. Typically, vaccines are aimed at ramping up the immune system to fight off infection, but this strategy eliminated that middle step.

"Traditional approaches toward developing an HIV vaccine that have worked for other viruses like influenza have just has not worked for HIV and, quite frankly, might not work for a long time or ever," explained the study's author, Dr. Philip R. Johnson, chief scientific officer at Children's Hospital of Philadelphia and a professor of pediatrics at the University of Pennsylvania School of Medicine.

"But Mother Nature has allowed us a few breaks, in that we know that in a very few cases, people who have been infected for a very long time have been able to naturally develop antibodies that neutralize a lot of the circulating virus," he said. "So, we thought perhaps we could take the genes that represent these antibodies 'off the shelf,' so to speak, give them directly to patients and, in essence, bypass the immune system."

"So, first we worked through mice and showed we could do it with mice," Johnson explained. "And now we've shown that we can actually transfer these genes into monkeys and protect these animals from SIV."

The findings are in the May 17 online issue of Nature Medicine.

The researchers' efforts focused on preventing SIV infection in nine macaque monkeys who were "immunized" against SIV by inserting genes already known to express anti-SIV antibodies directly into the monkeys' muscles.

Once the genes were injected, they prompted the muscles to produce antibodies that were released into the bloodstream and began attacking the SIV.

After being exposed to SIV four weeks later, six of the nine monkeys appeared to be fully protected from infection because they remained completely uninfected, and none of the nine immunized monkeys went on to develop AIDS or died from exposure to the virus, the researchers reported.

In contrast, six non-immunized monkeys exposed to SIV all became infected, and two-thirds died.

Johnson and his team concluded that their immunization strategy triggered the development of long-lasting and complete protection against SIV infection among monkeys.

"I'm not about to over-hype this," Johnson cautioned. "But we are continuing our work with monkeys in parallel with moving forward to begin human trials in two years, if everything goes perfectly with our work with the FDA to develop safety preparations, which is absolutely appropriate. And if the immunization trials work, then you have another few years to gear up. So, in the best of all possible worlds, you're looking at five years down the road for a practical benefit for patients. But, scientifically, we believe we are on the right track."

Rowena Johnston, director of research at the Foundation for AIDS Research in New York City, described the work as "one of the most interesting and potentially promising concepts to come out of the vaccine field in quite a while."

"They've cut straight to the chase and eliminated the middle man," she explained. "That is the really exciting thing they've done. We already all know that the traditional approaches to a vaccine won't work for HIV. And so HIV is a field where researchers are required to come up with ideas that nobody has needed to think about before, and that is where the challenge is. And here what they've done is to get antibodies to the virus themselves being produced directly, rather than waiting for the very slow-moving immune system to respond. And that is so elegant."

"Of course, the caveat is that this paper is a concept, and not yet a solution," Johnston noted. "But as concepts go, this is very, very interesting, even if it seems so obvious after you see it, like all good research."

More information

The World Health Organization has details on efforts to develop an HIV vaccine.



SOURCES: Philip R. Johnson, M.D., chief scientific officer, Children's Hospital of Philadelphia, and professor, pediatrics, University of Pennsylvania School of Medicine, Philadelphia; Rowena Johnston, Ph.D., vice president and director, research, Foundation for AIDS Research, New York City; May 17, 2009, Nature Medicine, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaccine Shields Monkeys From Simian Form of HIV
(Date:4/24/2017)... RICHEY, Fla. (PRWEB) , ... April 24, 2017 ... ... and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of ... slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health Management announced ... in people with addiction who are served by MAP’s patient engagement ecosystem. Lief ... that monitors heart and breath rates to identify anxiety levels and can provide ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new statin, ... not known to have significant interactions with antiretroviral therapy (ART). Among people ... and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Come to ... Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , ... our staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Donna Parker, ... but she has not found any of them to be very practical. She wanted ... slowly and easily make changes in their health. It prompted her in writing “ ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... 2017  Cardinal Health (NYSE: CAH ) ... earnings per share (EPS) guidance and providing a preliminary ... conjunction with this morning,s announcement of the planned acquisition ... Insufficiency businesses. Cardinal Health now believes that ... at the bottom of its previous guidance range of ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
Breaking Medicine Technology: